Weight Loss Drugs and Cardiovascular Risks
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Paul Poirier
- چاپ و سال / کشور: 2010
Description
Overweight and obesity have been rising dramatically worldwide and are an independent risk factor for cardiovascular disease (CVD). The majority of overweight and obese patients who achieve a significant short-term weight loss fail to maintain their lower weight in the long term. As a result, there has been focus on the role of pharmacotherapy for long-term weight management. Since the beginning, the quest for weight loss drugs has encountered warnings from regulatory agencies and withdrawals from the market. Accordingly, fenfluramine, dexfenfluramine, rimonabant, and sibutramine have been withdrawn from the market due to unacceptable side effects. Nevertheless, there is still intense research for the development of new anti-obesity compounds. The effect of these molecules on CVD risk factors has been reported, but one must remember that beyond CVD risk factor management, anti-obesity drugs should be safe for the long term.
Curr Cardiovasc Risk Rep (2011) 5:138–144 DOI 10.1007/s12170-010-0148-y Published online: 16 December 2010
